Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal
Year.
On September 24, 2021, the Board of Directors of Selecta Biosciences, Inc., a
Delaware corporation (the "Company"), approved an amendment to the Amended and
Restated Bylaws of the Company (the "Amendment"). The Amendment, which was
adopted effective September 24, 2021, changes the voting threshold required to
pass an amendment to the Amended and Restated Bylaws of the Company from
requiring the affirmative vote of the holders of at least two-thirds of the
voting power of the outstanding shares of capital stock of the Company entitled
to vote thereon, to requiring the affirmative vote of the holders of at least a
majority of the voting power of the outstanding shares of capital stock of the
Company entitled to vote thereon. A complete copy of the Company's bylaws in
effect following the approval by the Board of the Directors of the Amendment, is
filed with this Current Report on Form 8-K as Exhibit 3.2.
Item 7.01 Regulation FD Disclosure.
On September 29, 2021, the Company filed an investigational new drug application
with the U.S. Food and Drug Administration to conduct a Phase 1/2 clinical trial
of its SEL-302 product candidate in pediatric patients with methylmalonic
acidemia. SEL-302 is a combination therapeutic product candidate consisting of
MMA-101, an adeno-associated viral vector-based gene therapy candidate, and
SEL-110 (ImmTOR), an immune modulatory product candidate meant to ameliorate
unwanted immunogenicity of MMA-101.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
3.2 Amended and Restated Bylaws of Selecta Biosciences, Inc.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
CARTESIAN THERAPEUTICS, INC. 
